Ashland Inc
ASH
ISIN null / Valor 33989330
Ashland Inc
UMushroom community rating:
About company
Ashland Inc. is a global specialty chemicals company that plays a pivotal role in various industries by designing, synthesizing, and producing specialty additives and ingredients. These products find applications in a wide range of everyday items, enhancing their performance, quality, and consumer appeal. A notable area of Ashland's expertise is in the healthcare sector, where its Viatel™ platform of bioresorbable polymers is utilized in parenteral controlled release systems and medical device formulations. This technology underscores Ashland's commitment to innovation and its ability to address complex formulation challenges in the pharmaceutical and medical device industries. While the company has engaged in environmental, social, and governance initiatives, its core business revolves around leveraging advanced materials science to deliver specialized chemical solutions that meet the evolving needs of its customers across various markets.
Summarized from source with an LLMView SourceSector: IndustrialsLatest Results (04.10.2025):
Ashland Inc. reported its third quarter fiscal 2025 financial results, experiencing a decline in sales and net income compared to the same period last year. Despite facing a challenging market environment, the company focused on cost savings and operational efficiencies, resulting in adjusted EBITDA that aligns with expectations. The company also narrowed its full-year fiscal 2025 outlook range.
Sales Decline
Third-quarter sales were $463 million, a 15% decrease from $544 million in the prior-year quarter. Portfolio Optimization initiatives reduced sales by approximately $53 million (10%), with sales excluding these initiatives declining by five percent year-over-year.
Net Loss and Adjusted EBITDA
Ashland reported a net loss of $742 million, or ($16.21) per diluted share, compared to a net income of $6 million in the prior year. Adjusted EBITDA was $113 million, down 19% from the prior-year quarter, with Portfolio Optimization contributing to a $13 million decline.
Segment Performance
The Life Sciences segment saw sales decrease by 17% to $162 million, primarily due to Portfolio Optimization. Personal Care sales declined by 16% to $147 million, impacted by the divestiture of the Avoca business line. Specialty Additives and Intermediates also faced challenges, though Specialty Additives saw growth in other markets.
Cash Flow
Cash flows from operating activities were $114 million, a decrease from $128 million in the prior-year quarter. Ongoing Free Cash Flow totaled $108 million, slightly down from $112 million previously.
Operational Efficiency
Ashland continued to focus on cost savings and operational discipline, achieving lower selling, administrative, research, and development expenses through restructuring. The company also benefited from favorable foreign currency movements, which positively impacted sales and adjusted EBITDA.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
2302 M
Market cap (USD)
1,158,369
Daily traded volume (Shares)
71.49 / 70.4
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
